
ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist with experience in MDMA-assisted therapy research for PTSD and a private practice that includes ketamine-assisted psychotherapy. Alberding shares what it has been like to face a fatal neurodegenerative illness while working with ketamine in a structured clinical setting. Alberding explains that he was not looking for a casual psychedelic experience. He wanted help facing fear, grief, loss of function, and the reality of death. Over time, ketamine-assisted psychotherapy became a tool for processing those changes more directly than talk therapy alone had allowed.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

PT 654 - Erica Rex - Seeing What Is There

PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow

PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape
Free AI-powered recaps of Psychedelics Today and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.